Rovalpituzumab tesirine

N/A

Report date: 2024/02/05 13:55:44

Base Information

Drug NameRovalpituzumab tesirine
Drug Alias Name特罗伐妥组单抗rovalpituzumab tesirina特林-洛伐妥珠单抗rovalpituzumabum tesirinumRova-T +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SCX payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA damage stimulantsDNA cross linking agents
TargetsDelta-like protein 3DNA
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursProstatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAbbvie IncStemcentrx Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStemcentrx IncAbbvie IncAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Active IndicationsN/A
Inactive IndicationsMedullary thyroid cancer (MTC)Solid tumoursProstatic Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A